Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of KY-0301 monotherapy in advanced solid tumors
CTR20251136Phase 2Active
- Sponsor
- Keyi Bio
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KY-0301 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Keyi Bio. Started May 2025; status: active.
02
Drugs
KY-0301
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20251136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251136.